Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | ATP4A | P20648 | 2/20 | 0.31 |
| ▸ | ATP4B | P51164 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24656096 | 0.85 | CYP3A4 (0.33) | CYP3A4CYP2C9CYP11B2CYP11B1PDE10A | |
| SCHEMBL25104683 | 0.85 | ATP4A (0.34) | CYP3A4CYP2C9ATP4AATP4BCYP2D6 | |
| SCHEMBL7498143 | 0.81 | CYP3A4 (0.34) | CYP3A4CYP2C9CYP11B2CYP11B1PDE10A | |
| SCHEMBL16739601 | 0.81 | AKT1 (0.33) | AKT1AKT2 | |
| SCHEMBL25104409 | 0.81 | CYP3A4 (0.30) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL25103350 | 0.81 | NMT1 (0.33) | CYP3A4CYP2C9 | |
| SCHEMBL24654970 | 0.79 | AKT1 (0.32) | AKT1AKT2 | |
| SCHEMBL21893930 | 0.76 | F11 (0.35) | AKT1AKT2 | |
| SCHEMBL25311595 | 0.75 | MAPT (0.38) | CYP2C9CYP2C19CYP1A2 | |
| Potassium Ion SCHEMBL21819369 | 0.74 | HTR2A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | AKT1 2136/4885AKT2 2424/4885CYP3A4 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.